Bausch Health’s powerful near-term cash generation and discounted valuation offer asymmetric upside, but the Xifaxan patent cliff and $20.2 billion debt burden make deleveraging before 2028 decisive.
Overview
Bausch Health is a diversified specialty pharmaceutical and medical-device company whose core assets span Salix GI drugs, Solta aesthetics systems, international and legacy pharmaceuticals, and an approximately 86.9% stake in Bausch + Lomb. **Current operating momentum is strong:** Q2 2026 consolidated revenue reached $2.852 billion, up 13% reported and 11% organically; Adjusted EBITDA rose 28% to $1.075 billion, and Adjusted EPS increased 40% to $1.26. Salix revenue grew 21% and Solta 38%, and BHC ex-B+L recorded its 13th consecutive quarter of year-over-year revenue and Adjusted EBITDA growth. Management raised 2026 ex-B+L revenue guidance to $5.35–$5.50 billion and Adjusted EBITDA to $3.025–$3.100 billion. **The valuation is dominated by leverage and the approaching patent cliff:** $20.239 billion of principal debt and approximately $1.6 billion of annual interest sit against Xifaxan’s January 1, 2028 loss of exclusivity and CMS rebates beginning in 2027; 2027 Adjusted EBITDA is reaffirmed at $2.70 billion. At the report’s $5.80 share-price reference, BHC has roughly $22.4 billion enterprise value and trades at about 5.4x FY2026 consolidated Adjusted EBITDA guidance. The central near-term catalyst is continued cash generation and debt paydown ahead of Q3 results on October 28, 2026.